Literature DB >> 8849769

Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group.

A Auvinen1, J B Rietbergen, L J Denis, F H Schröder, P C Prorok.   

Abstract

To enable pooled analyses of continuing and planned randomised trials of prostate cancer screening, guidelines for minimal data required for such analyses were developed in the recent meeting of the International Prostate Screening Trial Evaluation Group (IPSTEG). The aim of the pooled analysis with data on individual level will be: (a) Estimation of the effect of screening on prostate cancer mortality with greater precision than individual studies (b) Assessment of optimal screening procedures and interval (c) Identification of subgroups within the populations that might receive most benefit from screening (d) Evaluation of the quality of life effects and cost effectiveness of screening. All studies included in the combined analysis share a common core protocol with minimum data requirements. The protocol allows, however, adaptation of the procedures to local circumstances within defined options. It should be noted that the process is continuing and the protocol is subject to evaluation and revision in the meetings of the IPSTEG on a regular basis.

Entities:  

Mesh:

Year:  1996        PMID: 8849769     DOI: 10.1177/096914139600300211

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  8 in total

1.  Epidemiological aspects of cancer screening in Germany.

Authors:  Nikolaus Becker
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-14       Impact factor: 4.553

Review 2.  Prostate cancer: 4. Screening.

Authors:  F Meyer; Y Fradet
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

3.  Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.

Authors:  R F Hoedemaeker; J B Rietbergen; R Kranse; T H van der Kwast; F H Schröder
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

4.  PSA screening and prostate cancer mortality.

Authors:  Linda Perron; Lynne Moore; Isabelle Bairati; Paul-Marie Bernard; François Meyer
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

Review 5.  Current status of PSA screening. Early detection of prostate cancer.

Authors:  Tom Pickles
Journal:  Can Fam Physician       Date:  2004-01       Impact factor: 3.275

6.  Adding free to total prostate-specific antigen levels in trials of prostate cancer screening.

Authors:  N J Wald; H C Watt; L George; P Knekt; K J Helzlsouer; J Tuomilehto
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 7.  A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study.

Authors:  Michela Meregaglia; Oriana Ciani; Helen Banks; Maximilian Salcher-Konrad; Caroline Carney; Sahan Jayawardana; Paula Williamson; Giovanni Fattore
Journal:  BMC Med Res Methodol       Date:  2020-02-27       Impact factor: 4.615

8.  Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Authors:  E L Turner; C Metcalfe; J L Donovan; S Noble; J A C Sterne; J A Lane; K N Avery; L Down; E Walsh; M Davis; Y Ben-Shlomo; S E Oliver; S Evans; P Brindle; N J Williams; L J Hughes; E M Hill; C Davies; S Y Ng; D E Neal; F C Hamdy; R M Martin
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.